Business

We are working on a drug discovery based on structural analysis using a Cryo-electron microscope (Cryo-EM).

What is a Cryo-EM?

 

 

Introduction of research achievements related to our Cryo-EM works
(including research achievements of our outside board members)

Member

Motoki Nakai
Chief Executive Officer
Osamu Nureki
Director
Yoshiyuki Kobayashi
VP / Chief Scientific Officer
Yuichi Matsubara
VP of Corporate & Business Development
Ayako Maita
Structural Biology Senior Researcher
Dan Sato
Structural Biology Senior Researcher
Katsumi Omagari
Structural Biology Senior Researcher
Yosuke Yamada
Scientific Development Senior Researcher

Advisor: Shunsuke Mori

Company Profile

Company Name Curreio, Inc.
HQ Location Room 357, South Clinical Research Laboratory, Tokyo University, 7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan, 113-8485
Representative CEO Motoki Nakai
Establishment August 2019
Capital Approximately 380 million yen (including capital reserve)
Business Contents Drug discovery and R & D business based on structural analysis using Cryo-EM
Legal Advisor Anderson Mōri & Tomotsune
Shareholders Beyond Next Ventures, Ono Venture Investment, Asahi Kasei Pharma, GEMSEKI, Etc.

 

Access

Office/Lab

Room 357, South Clinical Research Laboratory, Tokyo University,
7-3-1, Hongo, Bunkyo-ku, Tokyo, Japan, 113-8485

Currently, in order to strengthen the alert for COVID-19 at the University of Tokyo,
please call our staff when you arrive at the South Clinical Research Building.

Inquiry

We accept consultations and joint research on structure-based drug discovery (SBDD).

If you are interested, please contact us from the inquiry page.

MENU